Medina-González Ramón, Zaragoza Jose J, Hernández-Barajas Eduardo M, Correa-de Leon Juarez, Claure-Del Granado Rolando, Vazquez-Rangel Armando, Pineda-Segura Liliana M, Franco-Garcia Martha K, Chávez-Alonso Gael, Gómez-Fregoso Juan A, Rodríguez-García Francisco G, Navarro-Blackaller Guillermo, Alcantar-Vallin Luz, Gallardo-González Alejandro Martínez, Abundis-Mora Gabriela J, García-García Guillermo, Chávez-Iñiguez Jonathan S
Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico.
Intensive Care Unit, Hospital H + Queretaro, Mexico.
Ren Fail. 2024 Dec;46(1):2359643. doi: 10.1080/0886022X.2024.2359643. Epub 2024 Jun 13.
A reduction in platelet count in critically ill patients is a marker of severity of the clinical condition. However, whether this association holds true in acute kidney injury (AKI) is unknown. We analyzed the association between platelet reduction in patients with AKI and major adverse kidney events (MAKE).
In this retrospective cohort, we included AKI patients at the Hospital Civil of Guadalajara, in Jalisco, Mexico. Patients were divided according to whether their platelet count fell >21% during the first 10 days. Our objectives were to analyze the associations between a platelet reduction >21% and MAKE at 10 days (MAKE10) or at 30-90 days (MAKE30-90) and death.
From 2017 to 2023, 400 AKI patients were included, 134 of whom had > 21% reduction in platelet count. The mean age was 54 years, 60% were male, and 44% had sepsis. The mean baseline platelet count was 194 x 103 cells/µL, and 65% of the KDIGO3 patients met these criteria. Those who underwent hemodialysis (HD) had lower platelet counts. After multiple adjustments, a platelet reduction >21% was associated with MAKE10 (OR 4.2, CI 2.1-8.5) but not with MAKE30-90. The mortality risk increased 3-fold (OR 2.9, CI 1.1-7.7, = 0.02) with a greater decrease in the platelets (<90 x 103 cells/µL). As the platelets decreased, the incidence of MAKE was more likely to increase. These associations lost significance when accounting for starting HD.
In our retrospective cohort of patients with AKI, > 21% reduction in platelet count was associated with MAKE. Our results are useful for generating hypotheses and motivating us to continue studying this association with a more robust design.
危重症患者血小板计数降低是临床病情严重程度的一个指标。然而,这种关联在急性肾损伤(AKI)中是否成立尚不清楚。我们分析了AKI患者血小板减少与主要不良肾脏事件(MAKE)之间的关联。
在这项回顾性队列研究中,我们纳入了墨西哥哈利斯科州瓜达拉哈拉市民医院的AKI患者。根据患者在最初10天内血小板计数是否下降>21%进行分组。我们的目标是分析血小板减少>21%与10天时的MAKE(MAKE10)或30 - 90天时的MAKE(MAKE30 - 90)以及死亡之间的关联。
2017年至2023年,共纳入400例AKI患者,其中134例血小板计数下降>21%。平均年龄为54岁,60%为男性,44%患有脓毒症。平均基线血小板计数为194×10³个细胞/µL,65%的KDIGO3患者符合这些标准。接受血液透析(HD)的患者血小板计数较低。经过多次调整后,血小板减少>21%与MAKE10相关(OR 4.2,CI 2.1 - 8.5),但与MAKE30 - 90无关。血小板减少幅度更大(<90×10³个细胞/µL)时,死亡风险增加3倍(OR 2.9,CI 1.1 - 7.7,P = 0.02)。随着血小板减少,MAKE的发生率更有可能增加。在考虑开始HD后,这些关联失去了显著性。
在我们的AKI患者回顾性队列中,血小板计数降低>21%与MAKE相关。我们的结果有助于提出假设,并促使我们继续以更严谨的设计研究这种关联。